<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preeclampsia: Pathogenesis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preeclampsia: Pathogenesis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preeclampsia: Pathogenesis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Ananth Karumanchi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kee-Hak Lim, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Phyllis August, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vincenzo Berghella, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Preeclampsia is a syndrome characterized by the onset of hypertension and proteinuria or hypertension and end-organ dysfunction with or without proteinuria after 20 weeks of gestation  (<a class="graphic graphic_table graphicRef79977" href="/d/graphic/79977.html" rel="external">table 1</a>). Additional signs and symptoms that can occur include visual disturbances, headache, epigastric pain, thrombocytopenia, and abnormal liver function. These clinical manifestations result from mild to severe microangiopathy of target organs, including the brain, liver, kidney, and placenta [<a href="#rid1">1</a>]. Potential serious maternal sequelae include pulmonary edema, cerebral hemorrhage, hepatic failure, renal failure, and death. The fetal/neonatal burden of disease results from placental hypoperfusion and dysfunction and, in turn, the frequent need for preterm birth.</p><p>The pathophysiology of preeclampsia likely involves both maternal and fetal/placental factors. Abnormalities in the development of placental vasculature early in pregnancy may result in relative placental underperfusion/hypoxia/ischemia, which then leads to release of antiangiogenic factors into the maternal circulation that alter maternal systemic endothelial function and cause hypertension and other manifestations of the disease (hematologic, neurologic, cardiac, pulmonary, renal, and hepatic dysfunction). However, the trigger for abnormal placental development and the subsequent cascade of events remains unknown. </p><p>Our current understanding of mechanisms causing the pathologic changes observed in preeclampsia will be reviewed here. The clinical features and management of preeclampsia, and treatment of hypertension during pregnancy are discussed separately. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a> and  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ABNORMAL DEVELOPMENT OF THE PLACENTA</span><span class="headingEndMark"> — </span>The critical role of the placenta in the pathophysiology of preeclampsia, particularly early onset-preeclampsia, is supported by epidemiologic and experimental data that show:</p><p class="bulletIndent1"><span class="glyph">●</span>Placental tissue is necessary for development of the disease, but the fetus is not [<a href="#rid2">2-4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preeclampsia is always cured within days to weeks after delivery of the placenta; however, in rare cases postpartum hypertension and preeclampsia can occur up to 6 to 8 weeks postdelivery. The factors involved in the clinical expression of preeclampsia after delivery of the placenta are unclear, but may involve delayed clearance of antiangiogenic factors, activation of the complement system after delivery, and/or response to mobilization of extracellular fluid into the intravascular compartment [<a href="#rid5">5-7</a>]. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Natural history/course of disease'</a>.)</p><p></p><p>Examination of human placentas at various stages of gestation in women with normal pregnancies, as well as those with preeclampsia, has led to an understanding of normal placental morphology and pathologic changes in the uteroplacental circulation that are likely relevant to preeclampsia. It is clear that defects in spiral artery remodeling and trophoblast invasion, two related but separate processes, are characteristic of hypertensive disorders of pregnancy and fetal growth restriction [<a href="#rid8">8,9</a>]. These processes result in impaired placentation and placental ischemia, which are thought to be the primary events leading to placental release of soluble factors that cause systemic endothelial dysfunction resulting in the preeclamptic phenotype. (See <a class="local">'Role of systemic endothelial dysfunction in clinical findings'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Abnormal remodeling of spiral arteries</span><span class="headingEndMark"> — </span>In normal pregnancies, the cytotrophoblast cells of the developing placenta migrate through the decidua and part of the myometrium to invade both the endothelium and highly muscular tunica media of the maternal spiral arteries, the terminal branches of the uterine artery that supply blood to the developing fetus/placenta  (<a class="graphic graphic_figure graphicRef57301" href="/d/graphic/57301.html" rel="external">figure 1</a>). As a result, these vessels undergo transformation from small muscular arterioles to high capacitance vessels of low resistance, thus greatly facilitating blood flow to the placenta compared with other areas of the uterus [<a href="#rid10">10,11</a>]. Remodeling of the spiral arteries probably begins in the late first trimester and is completed by 18 to 20 weeks of gestation, although the exact gestational age at which trophoblast invasion of these arteries ceases is unclear.</p><p>By comparison, in preeclampsia, cytotrophoblast cells infiltrate the decidual portion of the spiral arteries but fail to penetrate the myometrial segment [<a href="#rid12">12,13</a>]. The spiral arteries fail to develop into large, tortuous vascular channels created by replacement of the musculoelastic wall with fibrinoid material; instead, the vessels remain narrow, resulting in placental hypoperfusion and relatively hypoxic trophoblast tissue  (<a class="graphic graphic_figure graphicRef61445" href="/d/graphic/61445.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef89125" href="/d/graphic/89125.html" rel="external">figure 3</a>). This defect in deep placentation has been associated with development of multiple adverse pregnancy outcomes, including second trimester fetal death, abruptio placentae, preeclampsia with or without intrauterine growth restriction, intrauterine growth restriction without maternal hypertension, preterm labor, and prelabor rupture of membranes [<a href="#rid14">14</a>]. </p><p>It is not known why the normal sequence of events in development of the uteroplacental circulation does not occur in some pregnancies. Vascular, environmental, immunological, and genetic factors all appear to play a role [<a href="#rid15">15</a>]. These factors will be reviewed in the following discussion.</p><p class="headingAnchor" id="H4"><span class="h2">Defective trophoblast differentiation</span><span class="headingEndMark"> — </span>Defective differentiation of trophoblast is one possible mechanism responsible for defective trophoblast invasion of the spiral arteries [<a href="#rid16">16</a>]. Trophoblast differentiation during endothelial invasion involves alteration in expression of a number of different classes of molecules, including cytokines, adhesion molecules, extracellular matrix molecules, metalloproteinases, and the class Ib major histocompatibility complex molecule, HLA-G [<a href="#rid17">17,18</a>]. During normal differentiation, invading trophoblasts alter their adhesion molecule expression from those that are characteristic of epithelial cells (integrin alpha6/beta1, alphav/beta5, and E-cadherin) to those of endothelial cells (integrin alpha1/beta1, alphav/beta3, and VE-cadherin), a process referred to as pseudo-vasculogenesis [<a href="#rid10">10</a>]. Trophoblasts obtained from women with preeclampsia do not show upregulated adhesion molecule expression or pseudo-vasculogenesis. </p><p>Transcriptomics and culture studies using human trophoblasts from women with severe preeclampsia have suggested that semaphorin 3B may be a candidate protein that contributes to the impaired trophoblast differentiation and invasion by inhibiting vascular endothelial growth factor signaling [<a href="#rid19">19</a>]. A laser microdissection approach enabled the identification of novel messenger RNAs and noncoding RNAs that were differentially expressed by various trophoblast subpopulations in severe preeclampsia [<a href="#rid20">20</a>]. Gene ontology analysis of the syncytiotrophoblast data highlighted the dysregulation of immune functions, morphogenesis, transport, and responses to vascular endothelial growth factor and progesterone. Additional studies are needed to evaluate the specific pathways that are disrupted.</p><p class="headingAnchor" id="H5"><span class="h2">Placental hypoperfusion, hypoxia, ischemia</span><span class="headingEndMark"> — </span>Hypoperfusion appears to be both a cause and a consequence of abnormal placental development. A causal relationship between poor placental perfusion, abnormal placental development, and preeclampsia is supported by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Animal models that have successfully reproduced at least some of the findings of preeclampsia have involved mechanically reducing uteroplacental blood flow [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical conditions associated with vascular insufficiency (eg, hypertension, diabetes, systemic lupus erythematosus, renal disease, acquired and inherited thrombophilias) increase the risk of abnormal placentation and preeclampsia [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obstetric conditions that increase placental mass without correspondingly increasing placental blood flow (eg, hydatidiform mole, hydrops fetalis, diabetes mellitus, twin and triplet gestation) result in relative ischemia and are associated with preeclampsia [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preeclampsia is more common in women who live at high altitudes (&gt;3100 meters) [<a href="#rid25">25</a>].</p><p></p><p>Hypoperfusion is also a result of abnormal placental development. Hypoperfusion becomes more pronounced as pregnancy progresses since the abnormal uterine vasculature is unable to accommodate the normal increase in blood flow to the fetus/placenta with increasing gestational age [<a href="#rid26">26-28</a>]. Late placental changes consistent with ischemia include atherosis (lipid-laden cells in the wall of the arteriole), fibrinoid necrosis, thrombosis, sclerotic narrowing of arterioles, and placental infarction [<a href="#rid10">10,26,27,29,30</a>]. Although all of these lesions are not uniformly found in patients with preeclampsia, there appears to be a correlation between the early onset and severity of the disease and the extent of these lesions [<a href="#rid31">31,32</a>].</p><p>Hypoperfusion, hypoxia, and ischemia are critical components in the pathogenesis of preeclampsia and, as pregnancy advances, are likely to be responsible for placental production of a variety of factors that, when released into the maternal bloodstream, secrete antiangiogenic factors (soluble fms-like tyrosine kinase-1 [sFlt-1] and endoglin) that bind vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), which results in widespread maternal vascular inflammation, endothelial dysfunction, and vascular injury, leading to hypertension, proteinuria, and the other clinical manifestations of preeclampsia [<a href="#rid22">22,33-40</a>]. (See <a class="local">'Role of systemic endothelial dysfunction in clinical findings'</a> below.)</p><p class="headingAnchor" id="H3408631282"><span class="h2">Decidual pathology</span><span class="headingEndMark"> — </span>Some studies have suggested that failed decidualization in some patients may lead to downregulated cytotrophoblast invasion [<a href="#rid41">41</a>]. Microarray studies of chorionic villus samples have also revealed a signature of impaired decidualization [<a href="#rid42">42</a>]. Interestingly, decidual cells from women with preeclampsia also overexpress sFLT1, suggesting that inadequate suppression of anti-angiogenic factors during the implantation period may lead to shallow implantation [<a href="#rid43">43</a>]. Additional work is needed to better understand endometrial antecedents in the genesis of preeclampsia. </p><p class="headingAnchor" id="H6"><span class="h1">IMMUNOLOGIC FACTORS</span><span class="headingEndMark"> — </span>The focus on immunologic factors as a possible contributor to abnormal placental development was based, in part, upon the observation that prior exposure to paternal/fetal antigens appears to protect against preeclampsia [<a href="#rid44">44-52</a>]. Nulliparous women and women who change partners between pregnancies, have long interpregnancy intervals, use barrier contraception, conceive in the first cycle of in vitro fertilization with same sperm donor, or conceive via intracytoplasmic sperm injection have less exposure to paternal antigens and higher risks of developing preeclampsia in some studies. In addition, meta-analyses have found that women who conceive through oocyte donation have a more than twofold higher rate of preeclampsia than women who conceive via other assisted reproductive techniques and a fourfold higher rate of preeclampsia than women who have a natural conception, which also supports the hypothesis that immunologic intolerance between the mother and fetus may play a role in the pathogenesis of preeclampsia [<a href="#rid53">53,54</a>].</p><p>Immunologic abnormalities, similar to those observed in organ rejection, have been observed in preeclamptic women [<a href="#rid55">55</a>]. The extravillous trophoblast (EVT) cells express an unusual combination of HLA class I antigens: HLA-C, HLA-E, and HLA-G. Natural killer (NK) cells that express a variety of receptors (CD94, KIR, and ILT) known to recognize class I molecules infiltrate the maternal decidua in close contact with the EVT cells [<a href="#rid56">56</a>]. Interaction between NK cells, and EVT cells has been hypothesized to regulate placental implantation. Additional regulators of immune tolerance at the maternal-fetal interface with potential relevance included regulatory T cells (Tregs), a specialized CD4 T cell subset that may play an important role in protecting the fetus by dampening the inflammatory immune response; these cells appear to be reduced in the systemic circulation as well as the placental bed in patients with preeclampsia [<a href="#rid57">57</a>]. In preeclampsia, conflict between maternal and paternal genes is believed to induce abnormal placental implantation through increased NK cell activity, decreased T regs, and other mediators of the immune response.</p><p>Placental bed biopsies from women with preeclampsia have revealed increased dendritic cell infiltration in preeclamptic decidual tissue [<a href="#rid58">58</a>]. The dendritic cells are an important initiator of antigen-specific T-cell responses to transplantation antigens. It is possible that increased number of dendritic cells may result in alteration in presentation of maternal and fetal antigens at the decidual level, leading to either abnormal implantation or altered maternal immunologic response to fetal antigens.</p><p>However, definitive evidence for this theory is lacking. Genetic studies looking at polymorphisms in the killer immunoglobulin receptors (KIR) on maternal NK cells and the fetal HLA-C haplotype suggest that women with KIR-AA genotype and fetal HLA-C2 genotype were at greatly increased risk of preeclampsia [<a href="#rid59">59</a>]. A systematic review found no clear evidence that one or several specific HLA alleles were involved in the pathogenesis of preeclampsia [<a href="#rid60">60</a>]. The authors suggested that interaction between maternal, paternal, and fetal HLA types, rather than any individual genotype alone, was probably an important factor to consider when studying immunogenetic determinants of preeclampsia. (See  <a class="medical medical_review" href="/d/html/3966.html" rel="external">"Immunology of the maternal-fetal interface"</a>.)</p><p>Another interesting finding is that patients with preeclampsia have increased levels of agonistic antibodies to the angiotensin AT-1 receptor. This antibody can mobilize intracellular free calcium and may account for increased plasminogen activator inhibitor-1 production and shallow trophoblast invasion seen in preeclampsia [<a href="#rid61">61-64</a>]. In addition, angiotensin AT-1 receptor antibody stimulates sFlt-1 secretion [<a href="#rid65">65</a>]. It is unclear if these alterations are pathogenic or epiphenomena. (See <a class="local">'Role of systemic endothelial dysfunction in clinical findings'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h1">GENETIC FACTORS</span><span class="headingEndMark"> — </span>Although most cases of preeclampsia are sporadic, genetic factors are thought to play a role in disease susceptibility in about one-third of cases [<a href="#rid66">66-76</a>]. A genetic predisposition to preeclampsia is suggested by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Primigravid women with a family history of preeclampsia (eg, affected mother or sister) have a two- to fivefold higher risk of the disease than primigravid women with no such history [<a href="#rid67">67,68,75,77</a>]. The maternal contribution to development of preeclampsia can be partially explained by imprinted genes [<a href="#rid78">78</a>]. In a study of sisters with preeclampsia, it was demonstrated that the mother developed preeclampsia only when the fetus/placenta inherited a maternal STOX1 missense mutation on 10q22; when the fetus/placenta carried the imprinted paternal homolog, the preeclampsia phenotype was not expressed. (See  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Parent-of-origin effects (imprinting)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of preeclampsia is increased more than sevenfold in women who have had preeclampsia in a previous pregnancy [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The spouses of men who were the product of a pregnancy complicated by preeclampsia are more likely to develop preeclampsia than spouses of men without this history [<a href="#rid69">69,75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A woman who becomes pregnant by a man whose previous partner had preeclampsia is at higher risk of developing the disorder than if the pregnancy with the previous partner was normotensive [<a href="#rid70">70</a>].</p><p></p><p>Although a study of preeclampsia in twins failed to find a genetic link [<a href="#rid80">80</a>], the bulk of data suggest that both maternal and paternal contributions to fetal genes may have a role in defective placentation and subsequent preeclampsia. </p><p>The genes for sFlt-1 and Flt-1 are carried on chromosome 13. Fetuses with an extra copy of this chromosome (eg, trisomy 13) should produce more of these gene products than their normal counterparts. In fact, the incidence of preeclampsia in mothers who carry fetuses with trisomy 13 is greatly increased compared with all other trisomies or with control pregnant patients [<a href="#rid81">81</a>]. In addition, the ratio of circulating sFlt-1 to PlGF is significantly increased in these pregnancies, thus accounting for their increased risk for preeclampsia [<a href="#rid82">82</a>]. A large genome-wide association study (GWAS) identified a genetic risk variant with genome-wide significance, and provided convincing replication in an independent cohort [<a href="#rid83">83</a>]. These findings were confirmed in additional European cohorts [<a href="#rid84">84</a>]. This GWAS finding provides compelling evidence that alterations in chromosome 13 near the <em>FLT1</em> locus in the human fetal genome are causal in the development of preeclampsia. (See <a class="local">'sFlt-1, VEGF, PlGF'</a> below.)</p><p>A meta-analysis reported studies of PAI-1 4G/5G polymorphism (recessive model) showed strong consistent evidence for an association with risk for preeclampsia [<a href="#rid54">54</a>]. Multiple maternal GWAS have reported potential susceptibility genes for preeclampsia, eclampsia, and gestational hypertension [<a href="#rid71">71,72,85-88</a>]. The largest of these evaluated the association of maternal DNA sequence variants with preeclampsia (&gt;20,000 cases and &gt;700,000 controls) and with gestational hypertension (&gt;11,000 cases and &gt;400,000 controls) across discovery and follow-up cohorts using multi-ancestry meta-analysis [<a href="#rid88">88</a>]. Eighteen independent genomic loci associated with preeclampsia/eclampsia and/or gestational hypertension were identified and supported the role of angiogenesis and endothelial function (<em>FLT1</em> and <em>ZBTB46</em>), natriuretic peptide signaling (<em>NPPA</em>, <em>NPR3</em> and <em>FURIN</em>), renal glomerular function (<em>TRPC6</em>, <em>TNS2</em> and <em>PLCE1</em>) and immune dysregulation (<em>MICA</em> and <em>SH2B3</em>) in the pathogenesis of these conditions, with some loci (<em>FLT1</em> and <em>WNT3A</em>) previously described to influence risk via the fetal genome. When the results were used to train and test polygenic risk scores for each outcome in independent datasets, polygenic risk score was modestly predictive of risk of a hypertensive disorder of pregnancy among nulliparous female individuals independent of first-trimester risk factors.</p><p>A locus at 12q may be linked to HELLP syndrome (ie, hemolysis, elevated liver enzymes, and low platelets), but not preeclampsia without severe features (ie, de novo hypertension and proteinuria), suggesting that genetic factors important in HELLP syndrome may be distinct from those in preeclampsia without severe features [<a href="#rid73">73</a>]. Alterations in long noncoding RNA at 12q23 have been implicated as one potential mechanism that may lead to HELLP syndrome [<a href="#rid89">89</a>]. This long noncoding RNA regulates a large set of genes that may be important for extravillous trophoblast migration.</p><p class="headingAnchor" id="H3360602991"><span class="h1">ENVIRONMENTAL AND MATERNAL SUSCEPTIBILITY FACTORS</span></p><p class="headingAnchor" id="H601772835"><span class="h2">Low calcium intake</span><span class="headingEndMark"> — </span>Various dietary and lifestyle factors have been associated with an increased risk of preeclampsia; however, causality has been difficult to prove. A possible role for low dietary intake of calcium as a risk factor for preeclampsia is suggested by epidemiologic studies linking low calcium intake with increased rates of preeclampsia and prevention of preeclampsia with calcium supplementation in high-risk women. The mechanism of this association is not clear but may involve either immunologic or vascular effects of calcium regulatory hormones that are altered in preeclampsia. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Calcium supplementation'</a>.)</p><p class="headingAnchor" id="H2659407524"><span class="h2">High body mass index</span><span class="headingEndMark"> — </span>A prospective study demonstrated a linear relationship between increasing body mass index and increasing risk of developing preeclampsia [<a href="#rid90">90</a>]. In this cohort, the odds ratio (OR) for preeclampsia rose from OR 1.65 in women with body mass index of 25 to 30 kg/m<sup>2 </sup>to OR 6.04 in women whose body mass index was ≥40 kg/m<sup>2</sup>. It is likely that obesity increases susceptibility to preeclampsia by inducing chronic inflammation and endothelial dysfunction, which may synergize with placental angiogenic factors to induce the microangiopathic features of preeclampsia [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H3784047671"><span class="h2">In vitro fertilization</span><span class="headingEndMark"> — </span>Compared with spontaneous conception, pregnancies after in vitro fertilization (IVF) have been associated with a higher risk of adverse pregnancy outcomes, including preeclampsia and fetal growth restriction [<a href="#rid92">92,93</a>]. The strength of association is greatest in oocyte donation pregnancies [<a href="#rid94">94,95</a>].</p><p class="headingAnchor" id="H3112758849"><span class="h1">INFLAMMATION</span><span class="headingEndMark"> — </span>Signs of maternal inflammation, which appear to be present in normal pregnancies at term, are exaggerated in preeclampsia. Circulating syncytiotrophoblast debris have been hypothesized to contribute to maternal inflammation and some of the features of the maternal syndrome [<a href="#rid96">96,97</a>]. Placental cell-free DNA released into the maternal circulation could play a role in driving the systemic inflammatory response of preeclampsia [<a href="#rid98">98</a>]. Placental hypoxia increases placental necrosis and apoptosis, which releases cell-free DNA into the maternal circulation. As early as 17 weeks of gestation, women who develop preeclampsia appear to have higher levels of trophoblast cell-free DNA compared with controls, with a sharp rise three weeks before clinical signs of preeclampsia become apparent [<a href="#rid99">99</a>]. The cell-free fetal DNA rise correlates with sFlt1 rise, and syncytial microparticles that carry the cell-free fetal DNA are loaded with sFlt1 and other toxic syncytial proteins [<a href="#rid100">100,101</a>]. It is likely that the inflammatory state may also increase the vascular endothelial sensitivity to toxic factors such as sFlt1 and sEng, although definitive evidence is lacking.</p><p>Maternal infection can also induce a systemic inflammatory response. A meta-analysis of observational studies that examined the relationship between maternal infection and preeclampsia reported that the risk of preeclampsia was increased in pregnant women with urinary tract infection (pooled odds ratio [OR] 1.57, 95% CI 1.45-1.70) and periodontal disease (pooled OR 1.76, 95% CI 1.43-2.18) [<a href="#rid102">102</a>]. There were no associations between preeclampsia and presence of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus; treated and nontreated HIV infection; malaria; herpes simplex virus type 2; bacterial vaginosis; or Mycoplasma hominis.</p><p class="headingAnchor" id="H1984121501"><span class="h1">INCREASED SENSITIVITY TO ANGIOTENSIN II</span><span class="headingEndMark"> — </span>Increased sensitivity to angiotensin II has been described in preeclampsia [<a href="#rid103">103</a>], and may be related to increased bradykinin (B2) receptor upregulation in preeclamptic patients. Upregulation leads to heterodimerization of B2 receptors with angiotensin II type I receptors (AT1), and this AT1/B2 heterodimer increases responsiveness to angiotensin II in vitro [<a href="#rid104">104</a>]. Interestingly, <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> therapy promoted AT1/B2 downregulation and prevented preeclampsia in a mouse model [<a href="#rid105">105</a>]. </p><p>As discussed above, patients with preeclampsia have increased levels of agonistic antibodies to the angiotensin AT-1 receptor. Angiotensin II is the endogenous ligand for the AT-1 receptor, thus increased activation of this receptor by auto-antibodies could induce the hypertension and vascular injury observed in preeclampsia. Studies in mice support this theory [<a href="#rid106">106,107</a>]. </p><p>Other studies in mice suggest that endothelial dysfunction induced by circulating anti-angiogenic factors are sufficient to induce angiotensin II sensitivity [<a href="#rid108">108</a>]. These studies have provided a strong biological rationale for studying compounds that improve endothelial health for the treatment of preeclampsia.</p><p class="headingAnchor" id="H3086249758"><span class="h1">COMPLEMENT ACTIVATION</span><span class="headingEndMark"> — </span>Increasing evidence suggests that complement dysregulation/activation may play a role in the pathogenesis of preeclampsia [<a href="#rid109">109,110</a>]. Preeclampsia is more common in pregnant women with autoimmune diseases, particularly systemic lupus erythematosus and the antiphospholipid antibody syndrome [<a href="#rid111">111,112</a>]. Activation of the classical pathway of complement in the placenta has been observed in such patients [<a href="#rid113">113,114</a>]. Preliminary clinical studies have reported increased markers of the alternative complement pathway activation in maternal serum and urine in women with severe preeclampsia [<a href="#rid115">115,116</a>]. In women without preexisting autoimmune disease, mutations in complement regulatory proteins have been shown to predispose to preeclampsia [<a href="#rid117">117</a>]. Germline mutations in the alternative complement pathway were also recently reported in hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, a severe complication of preeclampsia [<a href="#rid118">118</a>]. The similarities between HELLP syndrome and thrombotic microangiopathies in nonpregnant patients suggest that this is an interesting area of investigation with potential therapeutic applications [<a href="#rid119">119</a>].</p><p class="headingAnchor" id="H10"><span class="h1">ROLE OF SYSTEMIC ENDOTHELIAL DYSFUNCTION IN CLINICAL FINDINGS</span></p><p class="headingAnchor" id="H3860443440"><span class="h2">Overview</span><span class="headingEndMark"> — </span>All of the clinical features of preeclampsia can be explained as clinical responses to generalized endothelial dysfunction [<a href="#rid120">120,121</a>]. As an example, hypertension results from disturbed endothelial control of vascular tone, proteinuria and edema are caused by increased vascular permeability, and coagulopathy is the result of abnormal endothelial expression of procoagulants. Headache, seizures, visual symptoms, epigastric pain, and fetal growth restriction are the sequelae of endothelial dysfunction in the vasculature of target organs, such as the brain, liver, kidney, and placenta.</p><p>Laboratory evidence supporting generalized endothelial dysfunction in preeclamptic women includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased concentrations of circulating cellular fibronectin, factor VIII antigen, and thrombomodulin [<a href="#rid122">122-124</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired flow-mediated vasodilation [<a href="#rid125">125,126</a>] and impaired acetylcholine mediated vasorelaxation [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased production of endothelial-derived vasodilators, such as nitric oxide and prostacyclin, and increased production of vasoconstrictors, such as endothelins and thromboxanes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced vascular reactivity to angiotensin II [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum from preeclamptic women causes endothelial activation in human umbilical vein endothelial cell culture studies in some in vitro studies [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired endothelial function can be demonstrated by brachial artery flow-mediated dilation three years after a preeclamptic pregnancy [<a href="#rid129">129</a>]. It is unknown whether this is a cause or effect of the preeclamptic pregnancy.</p><p></p><p class="headingAnchor" id="H2187019252"><span class="h2">Preexisting maternal vascular/metabolic/kidney/autoimmune disease</span><span class="headingEndMark"> — </span>Rates of preeclampsia are significantly higher in women with comorbidities known to be associated with vascular disease, including hypertension, diabetes, chronic kidney disease, and autoimmune diseases. Although the precise pathophysiologic pathways relating these disorders to preeclampsia are not clear, preexisting endothelial cell damage may play a role [<a href="#rid130">130</a>]. Preexisting endothelial damage may also explain why women who develop preeclampsia are also at increased risk of developing cardiovascular disease later in life [<a href="#rid131">131,132</a>]. Women with a history of preeclampsia are also at increased risk for end stage renal disease and hypothyroidism in the long term [<a href="#rid133">133,134</a>]. (See  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Cardiovascular disease, kidney disease, type 2 diabetes'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">sFlt-1, VEGF, PlGF</span><span class="headingEndMark"> — </span>Mammalian placentation requires extensive angiogenesis for the establishment of a suitable vascular network to supply oxygen and nutrients to the fetus. A variety of proangiogenic (VEGF, PlGF) and antiangiogenic factors (sFlt-1) are elaborated by the developing placenta, and the balance among these factors is important for normal placental development. Increased production of antiangiogenic factors disturbs this balance and results in the systemic endothelial dysfunction characteristic of preeclampsia.</p><p>Soluble fms-like tyrosine kinase 1 (sFlt-1 or sVEGFR-1) is a naturally occurring, circulating antagonist to vascular endothelial growth factor (VEGF)  (<a class="graphic graphic_figure graphicRef54562" href="/d/graphic/54562.html" rel="external">figure 4</a>). VEGF is an endothelial specific mitogen that has a key role in promoting angiogenesis [<a href="#rid135">135,136</a>]. Its activities are mediated primarily by interaction with two high-affinity receptor tyrosine kinases, VEGFR-1 (VEGF receptor-1 or fms-like tyrosine kinase-1 [Flt-1]) and VEGFR-2 (kinase-insert domain region [KDR]/Flk-1), which are selectively expressed on the vascular endothelial cell surface. VEGFR-1 has two isoforms: a transmembranous isoform and a soluble isoform (sFlt-1 or sVEGFR-1). Placental growth factor (PlGF) is another member of the VEGF family that is made predominantly in the placenta. It also binds to the VEGFR-1 receptor. (See  <a class="medical medical_review" href="/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors", section on 'Vascular endothelial growth factor'</a>.)</p><p>sFlt-1 antagonizes the proangiogenic biologic activity of circulating VEGF and PlGF by binding to them and preventing their interaction with their endogenous receptors. Increased placental expression and secretion of sFlt-1 appear to play a central role in the pathogenesis of preeclampsia, based on the following observations [<a href="#rid108">108,137-146</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>sFlt-1 administered to pregnant rats induces albuminuria, hypertension, and the unique renal pathologic changes of glomerular endotheliosis  (<a class="graphic graphic_picture graphicRef78879 graphicRef59970 graphicRef68634" href="/d/graphic/78879.html" rel="external">picture 1A-C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transgenic overexpression of sFlt-1 in murine placentas led to impaired spiral artery remodeling and fetal growth restriction that was accompanied by maternal hypertension and proteinuria [<a href="#rid147">147</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In vitro, removal of sFlt-1 from supernatants of preeclamptic tissue culture restores endothelial function and angiogenesis to normal levels. Conversely, exogenous administration of VEGF and PlGF reverses the antiangiogenic state induced by excess sFlt-1. In pregnant mice, sFLT1 overexpression induces angiotensin II sensitivity and hypertension by impairing endothelial nitric oxide synthase activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with normotensive controls, circulating levels of sFlt-1 levels are increased and free VEGF and free PlGF are decreased in preeclamptic women. Studies using banked sera showed that preeclamptic women had decreases in PlGF and VEGF levels well before the onset of clinical disease [<a href="#rid144">144,148-153</a>]. For example:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A nested case-control study using banked sera to measure serum sFlt-1, as well as PlGF and VEGF, across gestation found that changes in sFlt-1 were predictive of the subsequent development of preeclampsia [<a href="#rid144">144</a>]. sFlt-1 levels increased during pregnancy in all women; however, compared with normotensive controls, women who went on to develop preeclampsia began this increase earlier in gestation (at 21 to 24 weeks versus 33 to 36 weeks) and reached higher levels  (<a class="graphic graphic_figure graphicRef74345" href="/d/graphic/74345.html" rel="external">figure 5</a>). A significant difference in the serum sFlt-1 concentration between the two groups was apparent five weeks before the onset of clinical disease. PlGF and VEGF levels fell concurrently with the rise in sFlt-1  (<a class="graphic graphic_figure graphicRef58442" href="/d/graphic/58442.html" rel="external">figure 6</a>), which may have been related, in part, to binding by sFlt-1.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another study, the concentration of sVEGFR-1 correlated with increasing severity of disease: sVEGFR-1 concentrations were higher in women with severe or early (&lt;34 weeks) preeclampsia than in those with mild or late preeclampsia [<a href="#rid141">141</a>]. Furthermore, women with preeclampsia had higher sVEGFR-1 levels than women who remained normotensive two to five weeks before onset of clinical disease [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alterations in both sFlt1 and PlGF correlate with adverse maternal and neonatal outcomes associated with preeclampsia [<a href="#rid112">112,154-159</a>].</p><p></p><p>In the aggregate, these observations suggest a major role for sFlt-1 and related angiogenic factors in the pathogenesis of at least some features of preeclampsia  (<a class="graphic graphic_figure graphicRef73060" href="/d/graphic/73060.html" rel="external">figure 7</a>) [<a href="#rid160">160</a>]. However, the trigger for increased sFlt-1 production by the placenta is unknown. The most likely trigger is placental ischemia [<a href="#rid161">161</a>]. In vitro, placental cytotrophoblasts possess a unique property to enhance sFlt-1 production when oxygen availability is reduced [<a href="#rid162">162</a>]. The increased expression of hypoxia-inducible transcription factors (HIFs) in preeclamptic placentas is consistent with this hypothesis [<a href="#rid163">163</a>]. It is not known whether increased sFlt-1 secretion is responsible for the early placental developmental abnormalities characteristic of preeclampsia or a secondary response to placental ischemia caused by some other factor. Genetic factors may also play a role in excess production of sFlt-1 and placental size (eg, multiple gestation) may play a role [<a href="#rid164">164</a>]. </p><p>Experimental studies in animals suggest that sFlt-1 leads to an exaggerated state of oxidative stress, which in turn adversely affects villous angiogenesis and increases sensitivity to vasopressors such as angiotensin II. These data suggest that endothelial dysfunction secondary to abnormal anti-angiogenic state may be the primary event leading to vasopressor sensitivity and hypertension [<a href="#rid108">108</a>]. It is likely that secondary, counter-regulatory systems may also play a role. For example, the renal disorder associated with preeclampsia, glomerular endotheliosis, leads to modest reductions in GFR and renal blood flow [<a href="#rid108">108</a>]. Alterations in the renin angiotensin system such as suppressed plasma renin activity in women with preeclampsia are consistent with sodium volume retention [<a href="#rid165">165</a>]. This sequence of events, similar to that observed in nonpregnant patients with glomerulonephritis, may also contribute to maternal hypertension.</p><p>Measurement of sFlt-1:PlGF ratio in serum appears to be a useful test to rule in or rule out preeclampsia in women with suspected preeclampsia [<a href="#rid166">166,167</a>]. In pregnant hypertensive women, a high plasma sFlt-1:PlGF identifies those at risk of requiring delivery within two weeks because of severe preeclampsia [<a href="#rid154">154,168</a>]. A large prospective study across 18 sites in the United States confirmed the prognostic utility of sFlt-1:PlGF in this population and noted that it outperformed all other standard-of-care tests for predicting preeclampsia with severe features within two weeks of presentation [<a href="#rid168">168</a>]. Based on the results of this study, in 2023 the United States Food and Drug Administration (FDA) approved the use of sFlt-1:PlGF to aid in the risk assessment of pregnant women with singleton pregnancies between 23+0 to 34+6 weeks of gestation and hospitalized for a hypertensive disorder of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) to predict progression to preeclampsia with severe features [<a href="#rid169">169</a>]. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Evidence'</a>.)</p><p>In the future, apheresis or drugs that reduce sFlt-1 levels or promote PlGF levels may be useful to prevent or treat preeclampsia [<a href="#rid170">170-174</a>]. Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy was highly effective in individuals with low PlGF levels measured during the first trimester [<a href="#rid175">175</a>]. Cell culture studies have shown aspirin may inhibit sFlt-1 production and could reverse angiogenic imbalance noted in preeclamptic placentae [<a href="#rid176">176</a>]. RNA interference therapies against sFlt-1 have also shown promise in nonhuman primate models of preeclampsia [<a href="#rid159">159</a>]. </p><p class="headingAnchor" id="H13"><span class="h2">Soluble endoglin</span><span class="headingEndMark"> — </span>It is likely that synergistic factors elaborated by the placenta other than sFlt-1 also play a role in the pathogenesis of the generalized endothelial dysfunction noted in preeclampsia. Consistent with this hypothesis is the observation that the plasma concentration of sFlt-1 protein needed to produce the preeclampsia phenotype in rats was severalfold higher than the levels typically seen in patients with preeclampsia, and no coagulation or liver function abnormalities were reported in the sFlt-1 treated animals [<a href="#rid137">137</a>].</p><p>Eng is a coreceptor for transforming growth factor (TGF)-beta and is highly expressed on cell membranes of vascular endothelium and syncytiotrophoblasts [<a href="#rid177">177</a>]. A novel placenta-derived soluble form of Eng, referred to as soluble endoglin (sEng), is an anti-angiogenic protein that appears to be another important mediator of preeclampsia [<a href="#rid104">104,177-179</a>].</p><p>Although the precise relationship of sEng to sFlt-1 is unknown, it appears that both sEng and sFlt-1 contribute to the pathogenesis of the maternal syndrome through separate mechanisms. Several lines of evidence support this hypothesis [<a href="#rid104">104,177-179</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>sEng is elevated in the sera of preeclamptic women two to three months before the onset of clinical signs of preeclampsia, correlates with disease severity, and falls after delivery. An increased level of sEng accompanied by an increased ratio of sFlt-1:PlGF is most predictive of developing preeclampsia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In vivo, sEng increases vascular permeability and induces hypertension. In pregnant rats, as an example, it appears to potentiate the vascular effects of sFlt-1 to induce a severe preeclampsia-like state, including the development of hemolysis, elevated liver function tests, low platelets (HELLP) syndrome and restriction of fetal growth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>sEng inhibits TGF-beta-1 signaling in endothelial cells and blocks TGF-beta-1 mediated activation of eNOS and vasodilation, suggesting that dysregulated TGF-beta signaling may be involved in the pathogenesis of preeclampsia.</p><p></p><p>Fetuses of preeclamptic mothers do not have high circulating concentrations of either sEng or sFlt-1 [<a href="#rid180">180</a>]. This suggests that fetuses do not experience proteinuria or hypertension like their mothers because they are not exposed to high concentrations of antiangiogenic factors.</p><p class="headingAnchor" id="H209396132"><span class="h1">PREECLAMPSIA IN THE PATHOGENESIS OF CARDIOVASCULAR DISEASE</span><span class="headingEndMark"> — </span>Although clinical signs and symptoms of preeclampsia resolve after placental delivery, affected women have a significantly elevated risk of developing chronic hypertension, ischemic heart disease, and stroke many years postpartum. In a meta-analysis, women diagnosed with preeclampsia had an approximately three-fold increased risk of developing hypertension and a twofold increased risk of heart attack and stroke compared with women without preeclampsia [<a href="#rid132">132</a>]. Patients at highest risk appear to be those with recurrent preeclampsia, preeclampsia with fetal compromise (fetal growth restriction or fetal death), or preeclampsia with severe features [<a href="#rid181">181-183</a>]. Preeclampsia is considered a risk-enhancing factor  (<a class="graphic graphic_table graphicRef131708" href="/d/graphic/131708.html" rel="external">table 2</a>) for informing and shaping the clinician-patient discussion of atherosclerotic cardiovascular disease risk and primary prevention therapies. (See  <a class="medical medical_review" href="/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p>Whether a pregnancy affected by preeclampsia directly accelerates cardiovascular disease, or prepregnancy shared risk factors contribute to development of both preeclampsia and cardiovascular disease, is not resolved. More data are needed to better understand the association between preeclampsia and accelerated cardiovascular disease and strategies to prevent cardiovascular disease in this large and expanding population of high-risk women. Available data are limited. In a large prospective cohort study of 5475 women, mid-trimester decreases in placental growth factor (a marker of angiogenic imbalance) was associated with larger left ventricular mass and higher average systolic blood pressure six to nine years after pregnancy compared with women with higher placental growth factor [<a href="#rid184">184</a>]. In a mouse model, exposure to preeclampsia induced angiotensin II sensitivity and exacerbated the vascular proliferative and fibrotic responses to future vascular injury [<a href="#rid185">185</a>].</p><p class="headingAnchor" id="H1269895606"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109729.html" rel="external">"Society guideline links: Hypertensive disorders of pregnancy"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/6720.html" rel="external">"Patient education: Preeclampsia (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular developmental factors</strong> – Development abnormalities of the uteroplacental circulation occur long before clinical manifestations of preeclampsia become evident. In preeclampsia, the cytotrophoblast infiltrates the decidual portion of the spiral arteries, but fails to penetrate the myometrial portion. Thus, the large, tortuous vascular channels characteristic of the normal placenta do not develop; instead, the vessels remain narrow, resulting in hypoperfusion and ischemia. Environmental, immunological, and genetic factors all appear to play a role in this process. (See <a class="local">'Abnormal development of the placenta'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic factors</strong> – The focus on immunologic factors as a possible contributor to the placental abnormality is based, in part, upon the observation that prior exposure to paternal/fetal antigens appears to protect against preeclampsia, as well as evidence of dysregulated immunity at the maternal-fetal interface. Alterations in circulating immunity, including a relative deficiency in regulatory T cells, and increased agonistic autoantibodies directed at the angiotensin-1 receptor have also been observed in women with preeclampsia. (See <a class="local">'Immunologic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic factors</strong> – Both maternal and paternal contributions to fetal genes may have a role in defective placentation and subsequent preeclampsia. In particular, a genetic locus on chromosome 13 appears to be associated with development of preeclampsia and may be responsible for the production of circulating anti-endothelial factors. (See <a class="local">'Genetic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endothelial factors </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endothelial cell function in preeclampsia </strong>– The ischemic placenta appears to elaborate factors (eg, antiangiogenic proteins, inflammatory cytokines) into the maternal bloodstream that alter maternal endothelial cell function and lead to the characteristic systemic signs and symptoms of preeclampsia. Many of the clinical features of preeclampsia can be explained as clinical responses to generalized endothelial dysfunction. (See <a class="local">'Role of systemic endothelial dysfunction in clinical findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>sFlt-1 and PlGF</strong> – Soluble fms-like tyrosine kinase 1 (sFlt-1) is a circulating antagonist to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). It is released by the diseased placenta  (<a class="graphic graphic_algorithm graphicRef79431" href="/d/graphic/79431.html" rel="external">algorithm 1</a>) and is an important mediator of the maternal signs and symptoms of preeclampsia. Soluble endoglin (sEng) appears to be another important mediator, but the precise relationship between sEng and sFlt-1 is unknown. (See <a class="local">'Role of systemic endothelial dysfunction in clinical findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preexisting vascular disease</strong> – There is a relationship between preexisting vascular disease, often present in women with comorbidities such as hypertension, diabetes, chronic kidney disease, and autoimmune diseases, and susceptibility to developing preeclampsia. Preexisting endothelial damage is often present in these disorders and may also explain why women who develop preeclampsia are also at increased risk of developing cardiovascular disease later in life. (See <a class="local">'Role of systemic endothelial dysfunction in clinical findings'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002; 287:3183.</a></li><li><a class="nounderline abstract_t">Moore-Maxwell CA, Robboy SJ. Placental site trophoblastic tumor arising from antecedent molar pregnancy. Gynecol Oncol 2004; 92:708.</a></li><li><a class="nounderline abstract_t">Nugent CE, Punch MR, Barr M Jr, et al. Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy. Obstet Gynecol 1996; 87:829.</a></li><li><a class="nounderline abstract_t">Matsuo K, Kooshesh S, Dinc M, et al. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 2007; 24:257.</a></li><li><a class="nounderline abstract_t">Goel A, Maski MR, Bajracharya S, et al. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation 2015; 132:1726.</a></li><li><a class="nounderline abstract_t">Skurnik G, Hurwitz S, McElrath TF, et al. Labor therapeutics and BMI as risk factors for postpartum preeclampsia: A case-control study. Pregnancy Hypertens 2017; 10:177.</a></li><li><a class="nounderline abstract_t">Ditisheim A, Sibai B, Tatevian N. Placental Findings in Postpartum Preeclampsia: A Comparative Retrospective Study. Am J Perinatol 2020; 37:1217.</a></li><li><a class="nounderline abstract_t">Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003; 69:1.</a></li><li><a class="nounderline abstract_t">Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006; 27:939.</a></li><li><a class="nounderline abstract_t">Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99:2152.</a></li><li><a class="nounderline abstract_t">Zhou Y, Damsky CH, Chiu K, et al. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993; 91:950.</a></li><li><a class="nounderline abstract_t">Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341:1447.</a></li><li><a class="nounderline abstract_t">Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101:669.</a></li><li><a class="nounderline abstract_t">Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol 2011; 204:193.</a></li><li><a class="nounderline abstract_t">Ilekis JV, Reddy UM, Roberts JM. Preeclampsia--a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci 2007; 14:508.</a></li><li><a class="nounderline abstract_t">Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51:970.</a></li><li><a class="nounderline abstract_t">Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: key pieces of the development puzzle. Science 1994; 266:1508.</a></li><li><a class="nounderline abstract_t">Lim KH, Zhou Y, Janatpour M, et al. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol 1997; 151:1809.</a></li><li><a class="nounderline abstract_t">Zhou Y, Gormley MJ, Hunkapiller NM, et al. Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest 2013; 123:2862.</a></li><li><a class="nounderline abstract_t">Gormley M, Ona K, Kapidzic M, et al. Preeclampsia: novel insights from global RNA profiling of trophoblast subpopulations. Am J Obstet Gynecol 2017; 217:200.e1.</a></li><li><a class="nounderline abstract_t">Casper FW, Seufert RJ. Atrial natriuretic peptide (ANP) in preeclampsia-like syndrome in a rat model. Exp Clin Endocrinol Diabetes 1995; 103:292.</a></li><li><a class="nounderline abstract_t">Makris A, Thornton C, Thompson J, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71:977.</a></li><li><a class="nounderline abstract_t">Dekker GA. Risk factors for preeclampsia. Clin Obstet Gynecol 1999; 42:422.</a></li><li><a class="nounderline abstract_t">Mastrobattista JM, Skupski DW, Monga M, et al. The rate of severe preeclampsia is increased in triplet as compared to twin gestations. Am J Perinatol 1997; 14:263.</a></li><li><a class="nounderline abstract_t">Palmer SK, Moore LG, Young D, et al. Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. Am J Obstet Gynecol 1999; 180:1161.</a></li><li><a class="nounderline abstract_t">Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol 1967; 93:581.</a></li><li><a class="nounderline abstract_t">Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1981; 88:876.</a></li><li><a class="nounderline abstract_t">Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1:177.</a></li><li><a class="nounderline abstract_t">Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93:1049.</a></li><li><a class="nounderline abstract_t">De Wolf F, Robertson WB, Brosens I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 1975; 123:164.</a></li><li><a class="nounderline abstract_t">Salafia CM, Pezzullo JC, Ghidini A, et al. Clinical correlations of patterns of placental pathology in preterm pre-eclampsia. Placenta 1998; 19:67.</a></li><li><a class="nounderline abstract_t">Walker JJ. Pre-eclampsia. Lancet 2000; 356:1260.</a></li><li><a class="nounderline abstract_t">Wang X, Athayde N, Trudinger B. A proinflammatory cytokine response is present in the fetal placental vasculature in placental insufficiency. Am J Obstet Gynecol 2003; 189:1445.</a></li><li><a class="nounderline abstract_t">Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004; 24:565.</a></li><li><a class="nounderline abstract_t">Roberts JM, Speer P. Antioxidant therapy to prevent preeclampsia. Semin Nephrol 2004; 24:557.</a></li><li><a class="nounderline abstract_t">Yinon Y, Nevo O, Xu J, et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008; 172:77.</a></li><li><a class="nounderline abstract_t">Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol 2007; 29:151.</a></li><li><a class="nounderline abstract_t">Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008; 59:61.</a></li><li><a class="nounderline abstract_t">Myatt L, Webster RP. Vascular biology of preeclampsia. J Thromb Haemost 2009; 7:375.</a></li><li><a class="nounderline abstract_t">Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011; 31:33.</a></li><li><a class="nounderline abstract_t">Garrido-Gomez T, Dominguez F, Quiñonero A, et al. Defective decidualization during and after severe preeclampsia reveals a possible maternal contribution to the etiology. Proc Natl Acad Sci U S A 2017; 114:E8468.</a></li><li><a class="nounderline abstract_t">Rabaglino MB, Conrad KP. Evidence for shared molecular pathways of dysregulated decidualization in preeclampsia and endometrial disorders revealed by microarray data integration. FASEB J 2019; 33:11682.</a></li><li><a class="nounderline abstract_t">Sahu MB, Deepak V, Gonzales SK, et al. Decidual cells from women with preeclampsia exhibit inadequate decidualization and reduced sFlt1 suppression. Pregnancy Hypertens 2019; 15:64.</a></li><li><a class="nounderline abstract_t">Robillard PY, Hulsey TC, Périanin J, et al. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 1994; 344:973.</a></li><li><a class="nounderline abstract_t">Koelman CA, Coumans AB, Nijman HW, et al. Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J Reprod Immunol 2000; 46:155.</a></li><li><a class="nounderline abstract_t">Wang JX, Knottnerus AM, Schuit G, et al. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 2002; 359:673.</a></li><li><a class="nounderline abstract_t">Einarsson JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol 2003; 188:1241.</a></li><li><a class="nounderline abstract_t">Smith GN, Walker M, Tessier JL, Millar KG. Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am J Obstet Gynecol 1997; 177:455.</a></li><li><a class="nounderline abstract_t">Klonoff-Cohen HS, Savitz DA, Cefalo RC, McCann MF. An epidemiologic study of contraception and preeclampsia. JAMA 1989; 262:3143.</a></li><li><a class="nounderline abstract_t">Mills JL, Klebanoff MA, Graubard BI, et al. Barrier contraceptive methods and preeclampsia. JAMA 1991; 265:70.</a></li><li><a class="nounderline abstract_t">Saftlas AF, Rubenstein L, Prater K, et al. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol 2014; 101-102:104.</a></li><li><a class="nounderline abstract_t">Hendin N, Meyer R, Peretz-Machluf R, et al. Higher incidence of preeclampsia among participants undergoing in-vitro fertilization after fewer sperm exposures. Eur J Obstet Gynecol Reprod Biol 2023; 285:12.</a></li><li><a class="nounderline abstract_t">Masoudian P, Nasr A, de Nanassy J, et al. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214:328.</a></li><li><a class="nounderline abstract_t">Giannakou K, Evangelou E, Papatheodorou SI. Genetic and non-genetic risk factors for pre-eclampsia: umbrella review of systematic reviews and meta-analyses of observational studies. Ultrasound Obstet Gynecol 2018; 51:720.</a></li><li><a class="nounderline abstract_t">Gleicher N. Why much of the pathophysiology of preeclampsia-eclampsia must be of an autoimmune nature. Am J Obstet Gynecol 2007; 196:5.e1.</a></li><li><a class="nounderline abstract_t">Loke YW, King A. Immunology of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:827.</a></li><li><a class="nounderline abstract_t">Santner-Nanan B, Peek MJ, Khanam R, et al. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009; 183:7023.</a></li><li><a class="nounderline abstract_t">Huang SJ, Chen CP, Schatz F, et al. Pre-eclampsia is associated with dendritic cell recruitment into the uterine decidua. J Pathol 2008; 214:328.</a></li><li><a class="nounderline abstract_t">Hiby SE, Walker JJ, O'shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200:957.</a></li><li><a class="nounderline abstract_t">Saftlas AF, Beydoun H, Triche E. Immunogenetic determinants of preeclampsia and related pregnancy disorders: a systematic review. Obstet Gynecol 2005; 106:162.</a></li><li><a class="nounderline abstract_t">Xia Y, Wen H, Bobst S, et al. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003; 10:82.</a></li><li><a class="nounderline abstract_t">Dechend R, Müller DN, Wallukat G, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol 2004; 24:571.</a></li><li><a class="nounderline abstract_t">Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101:2382.</a></li><li><a class="nounderline abstract_t">Thway TM, Shlykov SG, Day MC, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004; 110:1612.</a></li><li><a class="nounderline abstract_t">Zhou CC, Ahmad S, Mi T, et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51:1010.</a></li><li><a class="nounderline abstract_t">Lachmeijer AM, Dekker GA, Pals G, et al. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 2002; 105:94.</a></li><li><a class="nounderline abstract_t">Mogren I, Högberg U, Winkvist A, Stenlund H. Familial occurrence of preeclampsia. Epidemiology 1999; 10:518.</a></li><li><a class="nounderline abstract_t">Cincotta RB, Brennecke SP. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. Int J Gynaecol Obstet 1998; 60:23.</a></li><li><a class="nounderline abstract_t">Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001; 344:867.</a></li><li><a class="nounderline abstract_t">Lie RT, Rasmussen S, Brunborg H, et al. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ 1998; 316:1343.</a></li><li><a class="nounderline abstract_t">Arngrímsson R, Sigurõardóttir S, Frigge ML, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet 1999; 8:1799.</a></li><li><a class="nounderline abstract_t">Moses EK, Lade JA, Guo G, et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000; 67:1581.</a></li><li><a class="nounderline abstract_t">Lachmeijer AM, Arngrímsson R, Bastiaans EJ, et al. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet 2001; 9:758.</a></li><li><a class="nounderline abstract_t">Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. Am J Med Genet A 2004; 130A:365.</a></li><li><a class="nounderline abstract_t">Skjaerven R, Vatten LJ, Wilcox AJ, et al. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ 2005; 331:877.</a></li><li><a class="nounderline abstract_t">Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG 2004; 111:200.</a></li><li><a class="nounderline abstract_t">Carr DB, Epplein M, Johnson CO, et al. A sister's risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol 2005; 193:965.</a></li><li><a class="nounderline abstract_t">van Dijk M, Mulders J, Poutsma A, et al. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet 2005; 37:514.</a></li><li><a class="nounderline abstract_t">Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330:565.</a></li><li><a class="nounderline abstract_t">Treloar SA, Cooper DW, Brennecke SP, et al. An Australian twin study of the genetic basis of preeclampsia and eclampsia. Am J Obstet Gynecol 2001; 184:374.</a></li><li><a class="nounderline abstract_t">Tuohy JF, James DK. Pre-eclampsia and trisomy 13. Br J Obstet Gynaecol 1992; 99:891.</a></li><li><a class="nounderline abstract_t">Bdolah Y, Palomaki GE, Yaron Y, et al. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006; 194:239.</a></li><li><a class="nounderline abstract_t">McGinnis R, Steinthorsdottir V, Williams NO, et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nat Genet 2017; 49:1255.</a></li><li><a class="nounderline abstract_t">Kikas T, Inno R, Ratnik K, et al. C-allele of rs4769613 Near FLT1 Represents a High-Confidence Placental Risk Factor for Preeclampsia. Hypertension 2020; 76:884.</a></li><li><a class="nounderline abstract_t">Laasanen J, Hiltunen M, Romppanen EL, et al. Microsatellite marker association at chromosome region 2p13 in Finnish patients with preeclampsia and obstetric cholestasis suggests a common risk locus. Eur J Hum Genet 2003; 11:232.</a></li><li><a class="nounderline abstract_t">Laivuori H, Lahermo P, Ollikainen V, et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 2003; 72:168.</a></li><li><a class="nounderline abstract_t">Steinthorsdottir V, McGinnis R, Williams NO, et al. Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. Nat Commun 2020; 11:5976.</a></li><li><a class="nounderline abstract_t">Honigberg MC, Truong B, Khan RR, et al. Polygenic prediction of preeclampsia and gestational hypertension. Nat Med 2023; 29:1540.</a></li><li><a class="nounderline abstract_t">van Dijk M, Thulluru HK, Mulders J, et al. HELLP babies link a novel lincRNA to the trophoblast cell cycle. J Clin Invest 2012; 122:4003.</a></li><li><a class="nounderline abstract_t">Paré E, Parry S, McElrath TF, et al. Clinical risk factors for preeclampsia in the 21st century. Obstet Gynecol 2014; 124:763.</a></li><li><a class="nounderline abstract_t">Zera CA, Seely EW, Wilkins-Haug LE, et al. The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies. Am J Obstet Gynecol 2014; 211:247.e1.</a></li><li><a class="nounderline abstract_t">Chih HJ, Elias FTS, Gaudet L, Velez MP. Assisted reproductive technology and hypertensive disorders of pregnancy: systematic review and meta-analyses. BMC Pregnancy Childbirth 2021; 21:449.</a></li><li><a class="nounderline abstract_t">Johnson KM, Hacker MR, Thornton K, et al. Association between in vitro fertilization and ischemic placental disease by gestational age. Fertil Steril 2020; 114:579.</a></li><li><a class="nounderline abstract_t">Moreno-Sepulveda J, Checa MA. Correction to: Risk of adverse perinatal outcomes after oocyte donation: a systematic review and meta-analysis. J Assist Reprod Genet 2020; 37:239.</a></li><li><a class="nounderline abstract_t">Guilbaud L, Santulli P, Studer E, et al. Impact of oocyte donation on perinatal outcome in twin pregnancies. Fertil Steril 2017; 107:948.</a></li><li><a class="nounderline abstract_t">Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308:1592.</a></li><li><a class="nounderline abstract_t">Germain SJ, Sacks GP, Sooranna SR, et al. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178:5949.</a></li><li><a class="nounderline abstract_t">Hartley JD, Ferguson BJ, Moffett A. The role of shed placental DNA in the systemic inflammatory syndrome of preeclampsia. Am J Obstet Gynecol 2015; 213:268.</a></li><li><a class="nounderline abstract_t">Levine RJ, Qian C, Leshane ES, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 2004; 190:707.</a></li><li><a class="nounderline abstract_t">Rajakumar A, Cerdeira AS, Rana S, et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012; 59:256.</a></li><li><a class="nounderline abstract_t">Tannetta DS, Dragovic RA, Gardiner C, et al. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin. PLoS One 2013; 8:e56754.</a></li><li><a class="nounderline abstract_t">Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2008; 198:7.</a></li><li><a class="nounderline abstract_t">Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens 2001; 14:178S.</a></li><li><a class="nounderline abstract_t">AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7:1003.</a></li><li><a class="nounderline abstract_t">Quitterer U, Fu X, Pohl A, et al. Beta-Arrestin1 Prevents Preeclampsia by Downregulation of Mechanosensitive AT1-B2 Receptor Heteromers. Cell 2019; 176:318.</a></li><li><a class="nounderline abstract_t">Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14:855.</a></li><li><a class="nounderline abstract_t">Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 2011; 58:77.</a></li><li><a class="nounderline abstract_t">Burke SD, Zsengellér ZK, Khankin EV, et al. Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. J Clin Invest 2016; 126:2561.</a></li><li><a class="nounderline abstract_t">Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008; 198:385.e1.</a></li><li><a class="nounderline abstract_t">Alrahmani L, Willrich MAV. The Complement Alternative Pathway and Preeclampsia. Curr Hypertens Rep 2018; 20:40.</a></li><li><a class="nounderline abstract_t">Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163:153.</a></li><li><a class="nounderline abstract_t">Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 2016; 214:108.e1.</a></li><li><a class="nounderline abstract_t">Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644.</a></li><li><a class="nounderline abstract_t">Cohen D, Buurma A, Goemaere NN, et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 2011; 225:502.</a></li><li><a class="nounderline abstract_t">Burwick RM, Fichorova RN, Dawood HY, et al. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 2013; 62:1040.</a></li><li><a class="nounderline abstract_t">Guseh SH, Feinberg BB, Dawood HY, et al. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am J Reprod Immunol 2015; 73:437.</a></li><li><a class="nounderline abstract_t">Salmon JE, Heuser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011; 8:e1001013.</a></li><li><a class="nounderline abstract_t">Vaught AJ, Braunstein EM, Jasem J, et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 2018; 3.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Vercel C, Frémeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 2012; 7:2100.</a></li><li><a class="nounderline abstract_t">Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180:499.</a></li><li><a class="nounderline abstract_t">Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991; 4:700.</a></li><li><a class="nounderline abstract_t">Friedman SA, Schiff E, Emeis JJ, et al. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995; 172:202.</a></li><li><a class="nounderline abstract_t">Hsu CD, Iriye B, Johnson TR, et al. Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol 1993; 169:148.</a></li><li><a class="nounderline abstract_t">Taylor RN, Crombleholme WR, Friedman SA, et al. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991; 165:895.</a></li><li><a class="nounderline abstract_t">McCarthy AL, Woolfson RG, Raju SK, Poston L. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol 1993; 168:1323.</a></li><li><a class="nounderline abstract_t">Cockell AP, Poston L. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension 1997; 30:247.</a></li><li><a class="nounderline abstract_t">Pascoal IF, Lindheimer MD, Nalbantian-Brandt C, Umans JG. Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries. J Clin Invest 1998; 101:464.</a></li><li><a class="nounderline abstract_t">Roberts JM, Edep ME, Goldfien A, Taylor RN. Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence. Am J Reprod Immunol 1992; 27:101.</a></li><li><a class="nounderline abstract_t">Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285:1607.</a></li><li><a class="nounderline abstract_t">Levine RJ, Qian C, Maynard SE, et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006; 194:1034.</a></li><li><a class="nounderline abstract_t">Harskamp RE, Zeeman GG. Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 2007; 334:291.</a></li><li><a class="nounderline abstract_t">Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.</a></li><li><a class="nounderline abstract_t">Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359:800.</a></li><li><a class="nounderline abstract_t">Levine RJ, Vatten LJ, Horowitz GL, et al. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ 2009; 339:b4336.</a></li><li><a class="nounderline abstract_t">Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368.</a></li><li><a class="nounderline abstract_t">Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4.</a></li><li><a class="nounderline abstract_t">Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649.</a></li><li><a class="nounderline abstract_t">Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160:1405.</a></li><li><a class="nounderline abstract_t">Vuorela P, Helske S, Hornig C, et al. Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 2000; 95:353.</a></li><li><a class="nounderline abstract_t">Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88:2348.</a></li><li><a class="nounderline abstract_t">Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190:1541.</a></li><li><a class="nounderline abstract_t">McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191:1240.</a></li><li><a class="nounderline abstract_t">Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111:707.</a></li><li><a class="nounderline abstract_t">Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672.</a></li><li><a class="nounderline abstract_t">Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88:5555.</a></li><li><a class="nounderline abstract_t">Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95:884.</a></li><li><a class="nounderline abstract_t">Vogtmann R, Heupel J, Herse F, et al. Circulating Maternal sFLT1 (Soluble fms-Like Tyrosine Kinase-1) Is Sufficient to Impair Spiral Arterial Remodeling in a Preeclampsia Mouse Model. Hypertension 2021; 78:1067.</a></li><li><a class="nounderline abstract_t">Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188:177.</a></li><li><a class="nounderline abstract_t">Tjoa ML, van Vugt JM, Mulders MA, et al. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98:600.</a></li><li><a class="nounderline abstract_t">Su YN, Lee CN, Cheng WF, et al. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001; 97:898.</a></li><li><a class="nounderline abstract_t">Tidwell SC, Ho HN, Chiu WH, et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184:1267.</a></li><li><a class="nounderline abstract_t">Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101:1266.</a></li><li><a class="nounderline abstract_t">Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89:770.</a></li><li><a class="nounderline abstract_t">Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125:911.</a></li><li><a class="nounderline abstract_t">Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012; 25:2651.</a></li><li><a class="nounderline abstract_t">Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 2014; 27:132.</a></li><li><a class="nounderline abstract_t">March MI, Geahchan C, Wenger J, et al. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS One 2015; 10:e0126815.</a></li><li><a class="nounderline abstract_t">Rana S, Salahuddin S, Mueller A, et al. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens 2018; 13:100.</a></li><li><a class="nounderline abstract_t">Salahuddin S, Wenger JB, Zhang D, et al. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy 2016; 35:330.</a></li><li><a class="nounderline abstract_t">Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007; 109:168.</a></li><li><a class="nounderline abstract_t">Gilbert JS, Ryan MJ, LaMarca BB, et al. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294:H541.</a></li><li><a class="nounderline abstract_t">Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145:4838.</a></li><li><a class="nounderline abstract_t">Rajakumar A, Doty K, Daftary A, et al. Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae. Placenta 2003; 24:199.</a></li><li><a class="nounderline abstract_t">Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008; 198:428.e1.</a></li><li><a class="nounderline abstract_t">Buhl KB, Friis UG, Svenningsen P, et al. Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension 2012; 60:1346.</a></li><li><a class="nounderline abstract_t">Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med 2016; 374:13.</a></li><li><a class="nounderline abstract_t">Bian X, Biswas A, Huang X, et al. Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia. Hypertension 2019; 74:164.</a></li><li><a class="nounderline abstract_t">Thadhani R, Lemoine E, Rana S, et al. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid 2022.</a></li><li class="breakAll">Re: DEN220027. US Food and Drug Administration (FDA) approval letter. May 18, 2023. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf22/DEN220027.pdf (Accessed on September 01, 2023).</li><li><a class="nounderline abstract_t">Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124:940.</a></li><li><a class="nounderline abstract_t">Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108:1451.</a></li><li><a class="nounderline abstract_t">Rana S, Rajakumar A, Geahchan C, et al. Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1α pathway. FASEB J 2014; 28:4324.</a></li><li><a class="nounderline abstract_t">Thadhani R, Hagmann H, Schaarschmidt W, et al. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol 2016; 27:903.</a></li><li><a class="nounderline abstract_t">Matin M, Mörgelin M, Stetefeld J, et al. Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia. Hypertension 2020; 76:1176.</a></li><li><a class="nounderline abstract_t">Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2017; 50:492.</a></li><li><a class="nounderline abstract_t">Li C, Raikwar NS, Santillan MK, et al. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta 2015; 36:446.</a></li><li><a class="nounderline abstract_t">Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642.</a></li><li><a class="nounderline abstract_t">Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006; 21:3052.</a></li><li><a class="nounderline abstract_t">Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992.</a></li><li><a class="nounderline abstract_t">Staff AC, Braekke K, Johnsen GM, et al. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 2007; 197:176.e1.</a></li><li><a class="nounderline abstract_t">Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009; 114:961.</a></li><li><a class="nounderline abstract_t">Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005; 366:1797.</a></li><li><a class="nounderline abstract_t">Lykke JA, Langhoff-Roos J, Sibai BM, et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009; 53:944.</a></li><li><a class="nounderline abstract_t">Benschop L, Schalekamp-Timmermans S, Broere-Brown ZA, et al. Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy. Circulation 2019; 139:1698.</a></li><li><a class="nounderline abstract_t">Pruthi D, Khankin EV, Blanton RM, et al. Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. Hypertension 2015; 65:863.</a></li></ol></div><div id="topicVersionRevision">Topic 6760 Version 55.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12076198" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Contemporary concepts of the pathogenesis and management of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766272" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Placental site trophoblastic tumor arising from antecedent molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8677104" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17447188" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416810" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29153674" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Labor therapeutics and BMI as risk factors for postpartum preeclampsia: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31266066" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Placental Findings in Postpartum Preeclampsia: A Comparative Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12620937" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490251" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The uterine spiral arteries in human pregnancy: facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9151787" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7680671" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8099148" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pre-eclampsia: more than pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947500" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21094932" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The "Great Obstetrical Syndromes" are associated with disorders of deep placentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959880" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Preeclampsia--a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18259009" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Placental origins of preeclampsia: challenging the current hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985020" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Implantation and the placenta: key pieces of the development puzzle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403732" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23934129" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28347715" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Preeclampsia: novel insights from global RNA profiling of trophoblast subpopulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8536057" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Atrial natriuretic peptide (ANP) in preeclampsia-like syndrome in a rat model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377512" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451762" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk factors for preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9259940" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The rate of severe preeclampsia is increased in triplet as compared to twin gestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329872" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6054058" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The pathological response of the vessels of the placental bed to hypertensive pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7272259" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4669123" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The role of the spiral arteries in the pathogenesis of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790464" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1163579" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The ultrastructure of acute atherosis in hypertensive pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9481787" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical correlations of patterns of placental pathology in preterm pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11072961" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14634584" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A proinflammatory cytokine response is present in the fetal placental vasculature in placental insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15529291" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Preeclampsia and the systemic inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15529290" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antioxidant therapy to prevent preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156205" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17621700" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17937587" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Preeclampsia and angiogenic imbalance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19087223" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Vascular biology of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266263" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Angiogenic factors and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28923940" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Defective decidualization during and after severe preeclampsia reveals a possible maternal contribution to the etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356122" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evidence for shared molecular pathways of dysregulated decidualization in preeclampsia and endometrial disorders revealed by microarray data integration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30825929" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Decidual cells from women with preeclampsia exhibit inadequate decidualization and reduced sFlt1 suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7934427" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706945" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11879865" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748491" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sperm exposure and development of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9290468" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2810672" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An epidemiologic study of contraception and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984127" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Barrier contraceptive methods and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011785" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37028116" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Higher incidence of preeclampsia among participants undergoing in-vitro fertilization after fewer sperm exposures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26627731" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29143991" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Genetic and non-genetic risk factors for pre-eclampsia: umbrella review of systematic reviews and meta-analyses of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17240219" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Why much of the pathophysiology of preeclampsia-eclampsia must be of an autoimmune nature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11023803" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Immunology of implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915051" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18069648" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pre-eclampsia is associated with dendritic cell recruitment into the uterine decidua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477349" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994633" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immunogenetic determinants of preeclampsia and related pregnancy disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12593997" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15529292" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : AT1 receptor agonistic antibodies, hypertension, and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821814" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381659" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18259044" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381470" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Searching for preeclampsia genes: the current position.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468424" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Familial occurrence of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506410" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11259719" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Paternal and maternal components of the predisposition to preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563982" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Fetal and maternal contributions to risk of pre-eclampsia: population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441346" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035632" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781687" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A genome-wide scan for preeclampsia in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15384082" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169871" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961879" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157095" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A sister's risk: family history as a predictor of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806103" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743856" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228490" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : An Australian twin study of the genetic basis of preeclampsia and eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1450137" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pre-eclampsia and trisomy 13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16389038" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Circulating angiogenic proteins in trisomy 13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28628106" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Variants in the fetal genome near FLT1 are associated with risk of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32755415" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : C-allele of rs4769613 Near FLT1 Represents a High-Confidence Placental Risk Factor for Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12673277" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Microsatellite marker association at chromosome region 2p13 in Finnish patients with preeclampsia and obstetric cholestasis suggests a common risk locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12474145" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33239696" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37248299" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Polygenic prediction of preeclampsia and gestational hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23093777" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : HELLP babies link a novel lincRNA to the trophoblast cell cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198274" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clinical risk factors for preeclampsia in the 21st century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24631439" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34182957" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Assisted reproductive technology and hypertensive disorders of pregnancy: systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32709377" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association between in vitro fertilization and ischemic placental disease by gestational age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31834536" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Correction to: Risk of adverse perinatal outcomes after oocyte donation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283263" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Impact of oocyte donation on perinatal outcome in twin pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947178" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Latest advances in understanding preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442979" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794631" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The role of shed placental DNA in the systemic inflammatory syndrome of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042003" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215706" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23437230" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166297" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Maternal infection and risk of preeclampsia: systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11411754" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pathophysiology of pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533702" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30503206" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Beta-Arrestin1 Prevents Preeclampsia by Downregulation of Mechanosensitive AT1-B2 Receptor Heteromers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18660815" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576625" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27270170" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18221926" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29717384" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The Complement Alternative Pathway and Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26098843" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432463" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14660741" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21688269" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24060886" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25521546" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21445332" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29563339" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879435" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988826" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Preeclampsia: an excessive maternal inflammatory response to pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1930853" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7847535" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Biochemical corroboration of endothelial involvement in severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8392790" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Elevated circulating thrombomodulin in severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951550" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7682754" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Abnormal endothelial cell function of resistance arteries from women with preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9260988" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435319" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1418401" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11268269" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Association of maternal endothelial dysfunction with preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580293" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18030186" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Preeclampsia: at risk for remote cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975258" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18716297" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Preeclampsia and the risk of end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19920004" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409337" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9034784" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : The biology of vascular endothelial growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618519" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943725" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711543" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12727995" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284729" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507947" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618525" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764923" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Circulating angiogenic factors and the risk of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602804" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472115" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34397280" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Circulating Maternal sFLT1 (Soluble fms-Like Tyrosine Kinase-1) Is Sufficient to Impair Spiral Arterial Remodeling in a Preeclampsia Mouse Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548214" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576575" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Plasma placenta growth factor levels in midtrimester pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384693" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Decreased maternal serum placenta growth factor in early second trimester and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11349200" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798535" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764795" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22261192" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22861812" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687930" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25965397" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177034" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Angiogenic biomarkers in triage and risk for preeclampsia with severe features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028795" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17197602" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055511" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284201" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566247" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191808" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987920" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Urinary plasmin activates collecting duct ENaC current in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26735990" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31188674" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810665" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21187414" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24970393" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1αpathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405111" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32623922" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28741785" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : ASPRE trial: performance of screening for preterm pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638730" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751767" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Soluble endoglin contributes to the pathogenesis of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16870672" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957146" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17689641" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20168095" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16298217" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433776" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30760000" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712723" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Exposure to experimental preeclampsia in mice enhances the vascular response to future injury.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
